Bridget Crain, NP
Acute Care · Birmingham, ALNPI 1033660113
Payments from drug & device makers
Across 488 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Mallinckrodt Hospital Products Inc.$1K
- Boehringer Ingelheim$814
- Grifols USA, LLC$697
- Takeda Pharmaceuticals U.S.A., Inc.$531
- plus $4K from 34 others
What the payments were for
- Food & beverage$10,15499%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 78 | $1,622 |
| GSK | 78 | $1,483 |
| Mallinckrodt Hospital Products Inc. | 46 | $1,162 |
| Boehringer Ingelheim | 38 | $814 |
| Grifols USA, LLC | 32 | $697 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $531 |
| Merck | 21 | $431 |
| Regeneron Healthcare Solutions, Inc. | 22 | $416 |
| Amgen | 24 | $377 |
| United Therapeutics Corporation | 14 | $314 |
| Mylan Specialty L.p. | 13 | $271 |
| Gilead | 12 | $220 |
| Philips North America LLC | 10 | $200 |
| CSL Behring | 7 | $181 |
| Sanofi | 8 | $172 |
| Harmony Biosciences LLC | 5 | $140 |
| Vifor Pharma, Inc. | 5 | $134 |
| ANI Pharmaceuticals, Inc. | 5 | $105 |
| Viatris Specialty LLC | 4 | $81 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| Inogen, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 4 | $71 |
| La Jolla Pharmaceutical Company | 3 | $71 |
| Baxter Healthcare | 4 | $70 |
| Johnson & Johnson(2 entities) | 4 | $66 |
| Pfizer | 3 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Verona Pharma, Inc. | 2 | $44 |
| Pulmonx Corporation | 2 | $44 |
| Insmed, Inc. | 1 | $32 |
| Bayer | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Vapotherm Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$10,214 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $70,504 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $33,031 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,405 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $12,284 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,057 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,682 |
| Arnuity ElliptaFluticasone Furoate | 25 | $5,232 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,787 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,615 |
| Montelukast Sodium | 63 | $874 |
| Ipratropium Bromide | 18 | $786 |
| Fluticasone Propionate | 22 | $502 |
| Prednisone | 25 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,483 | $118,824226 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,622 | $18,08736 claims |
| Boehringer IngelheimCombivent Respimat | $814 | $12,28414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.
Other acute care in Birmingham
- Coretta CollinsBirmingham$77K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
- Michelle PriceBirmingham$13K
- Melissa FrenchBirmingham$13K
- Jaime CannonBirmingham$12K
- Kaci WeaverBirmingham$11K
- Alexandra GlennBirmingham$11K
- Rachel CookBirmingham$10K
- Kaitlyn JonesBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.